JP2009510051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510051A5 JP2009510051A5 JP2008532961A JP2008532961A JP2009510051A5 JP 2009510051 A5 JP2009510051 A5 JP 2009510051A5 JP 2008532961 A JP2008532961 A JP 2008532961A JP 2008532961 A JP2008532961 A JP 2008532961A JP 2009510051 A5 JP2009510051 A5 JP 2009510051A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- disease
- composition
- inflammatory
- inflammatory disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 208000027866 inflammatory disease Diseases 0.000 claims 23
- 238000000034 method Methods 0.000 claims 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 9
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 6
- 244000085223 Sphaeranthus indicus Species 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000006386 Bone Resorption Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000024279 bone resorption Effects 0.000 claims 3
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 230000003111 delayed effect Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000009610 hypersensitivity Effects 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 201000003068 rheumatic fever Diseases 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 229940047122 interleukins Drugs 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 102000015689 E-Selectin Human genes 0.000 claims 1
- 108010024212 E-Selectin Proteins 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1226MU2005 | 2005-09-30 | ||
| IN1226/MUM/2005 | 2005-09-30 | ||
| US73644305P | 2005-11-14 | 2005-11-14 | |
| US60/736,443 | 2005-11-14 | ||
| PCT/IB2006/053540 WO2007036900A2 (en) | 2005-09-30 | 2006-09-28 | Herbal composition for inflammatory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009510051A JP2009510051A (ja) | 2009-03-12 |
| JP2009510051A5 true JP2009510051A5 (https=) | 2009-10-01 |
| JP5331962B2 JP5331962B2 (ja) | 2013-10-30 |
Family
ID=37900158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532961A Expired - Fee Related JP5331962B2 (ja) | 2005-09-30 | 2006-09-28 | 炎症性疾患のための薬草組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7635494B2 (https=) |
| EP (1) | EP1931366B1 (https=) |
| JP (1) | JP5331962B2 (https=) |
| AU (1) | AU2006296197B2 (https=) |
| CA (1) | CA2624049C (https=) |
| EA (1) | EA014070B1 (https=) |
| GE (1) | GEP20115332B (https=) |
| MA (1) | MA29890B1 (https=) |
| PL (1) | PL1931366T3 (https=) |
| WO (1) | WO2007036900A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009016565A1 (en) * | 2007-07-27 | 2009-02-05 | Piramal Life Sciences Limited | Tricyclic compounds for the treatment of inflammatory disorders |
| US8383166B2 (en) * | 2007-12-03 | 2013-02-26 | Sequent Scientific Limited | Stable hydrophobic topical herbal formulationn |
| CA2751227C (en) | 2009-02-02 | 2021-10-26 | Laila Nutraceuticals | Composition from sphaeranthus indicus and garcinia mangostana for the control of metabolic syndrome |
| WO2012014216A1 (en) * | 2010-07-28 | 2012-02-02 | Laila Nutraceuticals | 7-hydroxyfrullanolide and its analogs for prevention, control and treatment of metabolic disorders |
| US10105347B2 (en) | 2009-02-02 | 2018-10-23 | Laila Nutraceuticals | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels |
| WO2011033524A2 (en) | 2009-08-04 | 2011-03-24 | Laila Nutraceuticals | Agents from ficus hispida for the amelioration of metabolic syndrome and related diseases |
| WO2011083397A1 (en) * | 2010-01-05 | 2011-07-14 | Himalaya Global Holdings Limited | Herbal composition for skin disorders |
| PH12013500451A1 (en) * | 2010-09-11 | 2013-05-20 | Laila Nutraceuticals | Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels |
| US8263579B2 (en) * | 2011-01-24 | 2012-09-11 | Piramal Healthcare Limited | Anti-inflammatory compounds |
| WO2014064609A2 (en) * | 2012-10-23 | 2014-05-01 | Piramal Enterprises Limited | HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES |
| US10792305B2 (en) | 2015-06-23 | 2020-10-06 | Nobilis Therapeutics, Inc. | Therapeutic immune modulation using noble gas compositions |
| BR112018073483B1 (pt) * | 2016-05-21 | 2022-08-23 | Laila Impex | Suplementos e composições dietéticas para a melhoria do desempenho físico e dos níveis de energia |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646687A (en) * | 1994-12-29 | 1997-07-08 | Lucent Technologies Inc. | Temporally-pipelined predictive encoder/decoder circuit and method |
| US6204523B1 (en) * | 1998-11-06 | 2001-03-20 | Lumileds Lighting, U.S., Llc | High stability optical encapsulation and packaging for light-emitting diodes in the green, blue, and near UV range |
| US6686676B2 (en) * | 2001-04-30 | 2004-02-03 | General Electric Company | UV reflectors and UV-based light sources having reduced UV radiation leakage incorporating the same |
| US6989412B2 (en) * | 2001-06-06 | 2006-01-24 | Henkel Corporation | Epoxy molding compounds containing phosphor and process for preparing such compositions |
| US6841647B2 (en) * | 2001-11-06 | 2005-01-11 | National Starch And Chemical Investment Holding Corporation | Fluid resistant silicone encapsulant |
| US7160972B2 (en) * | 2003-02-19 | 2007-01-09 | Nusil Technology Llc | Optically clear high temperature resistant silicone polymers of high refractive index |
| US7261441B2 (en) * | 2004-02-27 | 2007-08-28 | Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. | LED device and method for directing LED light |
| WO2006016228A2 (en) * | 2004-08-02 | 2006-02-16 | Prashanth Kumar V | Cytotoxic peptide alkaloid and pharmaceutical compositions for the treatment of neoplastic diseases |
| US7229934B2 (en) * | 2004-10-18 | 2007-06-12 | International Business Machines Corporation | Porous organosilicates with improved mechanical properties |
-
2006
- 2006-09-28 EA EA200800850A patent/EA014070B1/ru active IP Right Revival
- 2006-09-28 GE GEAP200610647A patent/GEP20115332B/en unknown
- 2006-09-28 EP EP06809434.1A patent/EP1931366B1/en active Active
- 2006-09-28 AU AU2006296197A patent/AU2006296197B2/en not_active Ceased
- 2006-09-28 JP JP2008532961A patent/JP5331962B2/ja not_active Expired - Fee Related
- 2006-09-28 PL PL06809434T patent/PL1931366T3/pl unknown
- 2006-09-28 WO PCT/IB2006/053540 patent/WO2007036900A2/en not_active Ceased
- 2006-09-28 CA CA2624049A patent/CA2624049C/en active Active
-
2008
- 2008-03-28 US US12/079,853 patent/US7635494B2/en active Active
- 2008-04-29 MA MA30886A patent/MA29890B1/fr unknown
-
2009
- 2009-07-09 US US12/500,057 patent/US8206756B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6166077A (en) | Use of L-acetylcarnitine, L-isovalerylcarnitine, L-propionylcarnitine for increasing the levels of IGF-1 | |
| JP2009510051A5 (https=) | ||
| JP2019052168A (ja) | オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ | |
| JP2003530349A (ja) | 皮膚病用の使用方法及び皮膚病用薬剤 | |
| AU2017287746A1 (en) | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same | |
| KR20150011379A (ko) | 옥시부티닌 투여를 위한 방법 및 조성물 | |
| CN101654393A (zh) | 作为肝脏保护剂的化合物和组合物 | |
| CN113546089A (zh) | 1-乙基-3，7-二甲基黄嘌呤在制备治疗肺炎药物中的应用 | |
| JP2025157438A5 (https=) | ||
| RU2006133305A (ru) | Применение 2, 5-дигидроксибензолсульфоновой кислоты для получения лекарственных препаратов, применяемых для лечения ангиозависимых заболеваний | |
| FI4199922T3 (fi) | (1r,3s)-3-((5-syano-4-fenyylitiatsol-2-yyli)karbamoyyli)syklopentaani-1-karboksyylihappo käytettäväksi hengitystietautien hoidossa | |
| CN112972391A (zh) | 一种胆红素-jph203纳米颗粒及其制备和应用 | |
| CN109260217A (zh) | 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用 | |
| CN105412118A (zh) | 治疗急慢性呼吸困难的西药组合物及其制备方法 | |
| CN103301118A (zh) | 注射用精氨酸布洛芬组合物 | |
| CN104000822A (zh) | 一种含有比拉斯汀的复方感冒药物组合物 | |
| CN118490680B (zh) | 瑞香素在制备治疗病毒性肺炎的药物中的应用 | |
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| Aggarwal et al. | Thalidomide-The disastrous drug | |
| RU2006140277A (ru) | Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, страдающих коронарной болезнью коронарной артерии | |
| US20260102376A1 (en) | Use of dihydrotanshinone i derivative in preparation of drug for treating cerebral cavernous malformation | |
| US20040092592A1 (en) | Stabilized L-Arginine platelet aggregation inhibitory compositions and processes for making same | |
| CN102283982B (zh) | 一种治疗体癣的药物组合物 | |
| JPS58164516A (ja) | 湿疹性皮膚疾患および薬疹治療剤 | |
| JP2001520644A (ja) | カルニチン化合物およびｄｈｅａまたはｄｈｅａ−ｓを含む造骨促進製剤 |